title: Adolescent use of the monthly contraceptive injection.
abstract: OBJECTIVE
  To compare weight and continuation among adolescents using monthly medroxyprogesterone acetate (MPA)/ethinyl estradiol cypionate (E2C), tri-monthly depot MPA (DMPA), and daily oral contraceptive pills (OCP).
  
  
  METHODS
  Medical records were reviewed for body mass index, demographics, and sexual history at baseline; and weight and continuation at 3, 6, 9, and 12 months. Bivariate analyses were performed by method, and continuation functions were compared by the log-rank and Wilcoxon tests. The effect of method on use duration was assessed by Cox regression.
  
  
  METHODS
  Hospital adolescent clinic.
  
  
  METHODS
  12- to 21-year-old patients who initiated MPA/E2C, DMPA, or OCPs in 2001.
  
  
  METHODS
  Weight gain and method continuation.
  
  
  RESULTS
  MPA/E2C was initiated by 40 (18%) patients, DMPA by 63 (28%), and OCPs by 119 (54%, P < 0.001). OCP users were younger (P = 0.005) and more likely to be white, privately insured, and in school (P < 0.004) than MPA/E2C or DMPA users. Previous DMPA and OCP use, pregnancy, and sexually transmitted infections (STI) were more common among MPA/E2C than DMPA or OCP users (P < or = 0.001). Baseline BMI was lowest (P = 0.06) among DMPA users, and MPA/E2C users were most likely to be overweight (P = 0.03). There were non-significant differences in weight change. Continuation functions differed by the method only in the first three months of use (P = 0.03). Leading reasons for discontinuation were unavailability of MPA/E2C (20%), bleeding with DMPA (22%), and forgetting OCPs (17%). Duration of use was independently associated with white race (P < 0.005) and STI-never (P < 0.0001) but not with method type.
  
  
  CONCLUSIONS
  Although MPA/E2C use was associated with overweight status and early discontinuation, it also was associated with previous use of other methods. For all methods, poor continuation at one year supports the ongoing search for effective contraceptive alternatives.
authors.affiliation: Pediatric Residency Training Program, Cincinnati Children's Hospital Medical Center, Ohio, USA. tuchman1@email.chop.edu
authors.forename: Lisa Kessler
authors.initials: LK
authors.lastname: Tuchman
authors.forename: Jill S
authors.initials: JS
authors.lastname: Huppert
authors.forename: Bin
authors.initials: B
authors.lastname: Huang
authors.forename: Gail B
authors.initials: GB
authors.lastname: Slap
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D003268:Contraception Behavior; D003271:Contraceptive Agents, Female / Q000008:administration & dosage*; D003276:Contraceptives, Oral; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage*; D012189:Retrospective Studies; D015430:Weight Gain
chemical_list: D003271:Contraceptive Agents, Female; D003276:Contraceptives, Oral; D004958:Estradiol; C007630:estradiol 17 beta-cypionate; D017258:Medroxyprogesterone Acetate